Update and Arizona Thoracic Society position statement on stem cell therapy for lung disease

Southwest Journal of Pulmonary and Critical Care

Arizona Thoracic Society¹ 

[1] Phoenix Pulmonary and Critical Care Research and Education Foundation, Gilbert, AZ USA;

关键词: adult respiratory distress syndrome;    review;    stem cell;    transplantation;    therapy;    COPD;    chronic obstructive pulmonary disease;    idiopathic pulmonary fibrosis;    cystic fibrosis;    outcomes;   

DOI  :  10.13175/swjpcc020-19

来源: DOAJ

【 摘 要 】

Infusions of stem cells are increasingly being offered for a variety of diseases, including chronic lung diseases such as chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and cystic fibrosis. However, the potential for harm, the lack of any proven benefit, and the high fees that many of these programs charge make recommending stem cell therapy untenable. At the time of this writing (April 2019) it appears that stem cell therapy can be safely performed, although the long-term side effects remain unknown. However, the little data available show no benefit in meaningful outcomes, such as mortality, morbidity or patient well-being, for stem cell treatment of chronic lung disorders. Patients with severe, incurable diseases may be motivated to seek innovative therapies. We encourage such patients to contact their primary care physician or pulmonologist. Clinical trials in the United States and Canada investigating stem cell therapy for lung diseases can be found on the website of the National Institutes of Health at Clinicaltrials.gov. The Arizona Thoracic Society encourages regulatory agencies to protect the public health and take appropriate action against non-investigational, for-profit stem cell clinics when appropriate.

【 授权许可】

Unknown